Deep Bio's AI-based Antibody Optimization Platform Applied to Parkinson's Disease
Retrieved on:
Friday, August 13, 2021
Time, Drug discovery, Prostate, Parkinson's disease, CEO, Pathology, University, Deep learning, Medicine, Partnership, Research, Laboratory, Antibody, Prognosis, Patient, VisionAire 500K, Medical device, Technology, H&E, AI, IVD, Diagnosis, MFDS, Workload, R, Marie Cassidy, Prostate cancer, Medical imaging
The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.
Key Points:
- The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.
- The antibody under study, if successful, has the potential to become an effective treatment option for patients with Parkinson's disease.
- Utilizing our AI-based algorithm will dramatically reduce the time and cost for drug optimization," said the CEO of Deep Bio.
- Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.